Chronic Obstructive Pulmonary Disease Market: By Treatment, By Drug Class By Disease Type, By End Users and Geography

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Chronic Obstructive Pulmonary Disease (COPD) Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment (Drugs, Surgery, Oxygen Therapy, and Others), By Drug Class (Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, and Others) By Disease Type (Chronic Bronchitis and Emphysema), By End Users (Hospitals, Clinics, Homecare, Others) and Region

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Chronic Obstructive Pulmonary Disease (COPD) Market size was valued at US$ 21.2 billion in 2023 and is poised to grow at a CAGR of 4.8% over 2024-2030. Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by long-term respiratory symptoms and airflow limitation, including symptoms such as shortness of breath and a cough, and the causes include tobacco smoking, air pollution, and genetics. Based on the drug class, the combination therapy segment is anticipated to dominate the market share over the forecast period.

According to the World Health Organization, COPD is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. The increasing incidences of respiratory disorders and growing awareness will act as the chronic obstructive pulmonary disease market growth driver, whereas, the high cost of treatment would be the lagging factor for the market. The rise in chronic obstructive pulmonary disease market demand for novel drug therapies and an increase in investments by key market players are opportunities for the expansion of the market. 

Chronic Obstructive Pulmonary Disease (COPD) Market Key Developments:

  • In Oct 2021, Mylan Pharmaceuticals received FDA approval for its investigational new drug application for Breyna (Budesonide and Formoterol fumarate dihydrate inhalation aerosol), for the treatment of asthma and COPD.
  • In April 2022, GSK launched Trelegy Ellipta, a single-inhaler triple therapy for COPD patients.

summary download arrow Download Free Sample

Chronic Obstructive Pulmonary Disease Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.8%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Chronic Obstructive Pulmonary Disease (COPD) Market Dynamics

With an increase in the incidence of COPD, awareness programs, and adoption of effective treatments are also increasing, so the advancements in technologies for drug development are the major factors for the market growth. For instance, in Feb 2021, Sanofi, in collaboration with Regeneron Pharmaceuticals, initiated a phase-III clinical trial for Itepekimab, in moderate-to-severe COPD. Thus, the increased awareness, research, and development for chronic disorders will lead to the growth of the market within the forecast period. However, side effects and risks associated with COPD drugs could be a negative factor for the market growth.

Chronic Obstructive Pulmonary Disease Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 21.2 billion

Market CAGR

4.8%

By Treatment

  • Drugs
  • Surgery
  • Oxygen Therapy
  • Others

By Drug Class

  • Combination Therapy
  • Bronchodilators
  • Corticosteroids
  • Phosphodiesterase Type 4 Inhibitor
  • Mucokinetics
  • Others

By Disease Type

  • Chronic Bronchitis
  • Emphysema

By End User

  • Hospitals
  • Clinics
  • Homecare
  • Others

Key Features of the Report

  • The chronic obstructive pulmonary disease (COPD) market report provides granular level information about the market size, regional market share, historic market (2019-2024) and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The global chronic obstructive pulmonary disease market size was valued at US$ 21.2 billion in 2023 and is projected to grow at a CAGR of 4.8% by 2030.

The rise in demand for novel drug therapies and an increase in investments are the key opportunities for the Chronic Obstructive Pulmonary Disease (COPD) market.

The increasing incidences of respiratory disorders and growing awareness are the growth drivers in the Chronic Obstructive Pulmonary Disease (COPD) market.

Boehringer Ingelheim International GmbH, GlaxoSmithKline plc., Novartis International AG, AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Amneal Pharmaceuticals LLC., Mylan N.V., and OptiNose US Inc. are a few companies operating in the Chronic Obstructive Pulmonary Disease (COPD) market.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Chronic Obstructive Pulmonary Disease Market Introduction 
2.1.Global Chronic Obstructive Pulmonary Disease Market  - Taxonomy
2.2.Global Chronic Obstructive Pulmonary Disease Market  - Definitions
2.2.1.Treatment
2.2.2.Drug Class
2.2.3.Disease Type
2.2.4. End User
2.2.5.Region
3.Global Chronic Obstructive Pulmonary Disease Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Chronic Obstructive Pulmonary Disease Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Chronic Obstructive Pulmonary Disease Market  By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Drugs
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Surgery
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Oxygen Therapy
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Chronic Obstructive Pulmonary Disease Market  By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Combination Therapy
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Bronchodilators
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Corticosteroids
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Phosphodiesterase Type 4 Inhibitor
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Mucokinetics
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Others
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
7.Global Chronic Obstructive Pulmonary Disease Market  By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Chronic Bronchitis
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Emphysema
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
8.Global Chronic Obstructive Pulmonary Disease Market  By  End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Hospitals
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Clinics
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Homecare
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Others
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
9.Global Chronic Obstructive Pulmonary Disease Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Chronic Obstructive Pulmonary Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Drugs
10.1.2.Surgery
10.1.3.Oxygen Therapy
10.1.4.Others
10.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Combination Therapy
10.2.2.Bronchodilators
10.2.3.Corticosteroids
10.2.4.Phosphodiesterase Type 4 Inhibitor
10.2.5.Mucokinetics
10.2.6.Others
10.3.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Chronic Bronchitis
10.3.2.Emphysema
10.4.   End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospitals
10.4.2.Clinics
10.4.3.Homecare
10.4.4.Others
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Chronic Obstructive Pulmonary Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Drugs
11.1.2.Surgery
11.1.3.Oxygen Therapy
11.1.4.Others
11.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Combination Therapy
11.2.2.Bronchodilators
11.2.3.Corticosteroids
11.2.4.Phosphodiesterase Type 4 Inhibitor
11.2.5.Mucokinetics
11.2.6.Others
11.3.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Chronic Bronchitis
11.3.2.Emphysema
11.4.   End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospitals
11.4.2.Clinics
11.4.3.Homecare
11.4.4.Others
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Chronic Obstructive Pulmonary Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Drugs
12.1.2.Surgery
12.1.3.Oxygen Therapy
12.1.4.Others
12.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Combination Therapy
12.2.2.Bronchodilators
12.2.3.Corticosteroids
12.2.4.Phosphodiesterase Type 4 Inhibitor
12.2.5.Mucokinetics
12.2.6.Others
12.3.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Chronic Bronchitis
12.3.2.Emphysema
12.4.   End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospitals
12.4.2.Clinics
12.4.3.Homecare
12.4.4.Others
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Chronic Obstructive Pulmonary Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Drugs
13.1.2.Surgery
13.1.3.Oxygen Therapy
13.1.4.Others
13.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Combination Therapy
13.2.2.Bronchodilators
13.2.3.Corticosteroids
13.2.4.Phosphodiesterase Type 4 Inhibitor
13.2.5.Mucokinetics
13.2.6.Others
13.3.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Chronic Bronchitis
13.3.2.Emphysema
13.4.   End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospitals
13.4.2.Clinics
13.4.3.Homecare
13.4.4.Others
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Chronic Obstructive Pulmonary Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Drugs
14.1.2.Surgery
14.1.3.Oxygen Therapy
14.1.4.Others
14.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Combination Therapy
14.2.2.Bronchodilators
14.2.3.Corticosteroids
14.2.4.Phosphodiesterase Type 4 Inhibitor
14.2.5.Mucokinetics
14.2.6.Others
14.3.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Chronic Bronchitis
14.3.2.Emphysema
14.4.   End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospitals
14.4.2.Clinics
14.4.3.Homecare
14.4.4.Others
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Boehringer Ingelheim International GmbH
15.2.2.GlaxoSmithKline plc.
15.2.3.Novartis International AG
15.2.4.AstraZeneca
15.2.5.Pfizer Inc.
15.2.6.Teva Pharmaceutical Industries Ltd.
15.2.7.Merck & Co.
15.2.8.Amneal Pharmaceuticals LLC.
15.2.9.Mylan N.V.
15.2.10.OptiNose US Inc.
16. Research Methodology 
17. Appendix and Abbreviations 

Key Market Players

  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc.
  • Novartis International AG
  • AstraZeneca
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co.
  • Amneal Pharmaceuticals LLC.
  • Mylan N.V.
  • OptiNose US Inc.

Related Industry Reports

Chronic Refractory Gout Pharmaceuticals Market

Familial Mediterranean Fever Pharmaceuticals Market

Australia Point of Care Diagnostics Market

Aseptic Sampling Market